Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.35 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315087 | 0.86 | CCR5 (0.38) | CCR5LMNARAB9AALDH1A1HTR7 | |
| SCHEMBL1315086 | 0.86 | CCR5 (0.38) | CCR5LMNARAB9AALDH1A1HTR7 | |
| SCHEMBL14480694 | 0.84 | CCR5 (0.35) | CCR5LMNARAB9AALDH1A1HTR7 | |
| SCHEMBL1311395 | 0.80 | ELANE (0.47) | CCR5LMNARAB9AALDH1A1ELANE | |
| SCHEMBL4016266 | 0.77 | CCR5 (0.42) | CCR5LMNARAB9AALDH1A1ELANE | |
| SCHEMBL5969107 | 0.77 | CCR5 (0.42) | CCR5LMNARAB9AALDH1A1ELANE | |
| SCHEMBL7792091 | 0.76 | CNR2 (0.40) | LMNASMN1; SMN2HTT | |
| SCHEMBL5521929 | 0.76 | NFKB1 (0.42) | LMNACYP1A2 | |
| SCHEMBL27529171 | 0.75 | EGFR (0.43) | RAB9APRMT5WDR77SMN1; SMN2 | |
| SCHEMBL27529170 | 0.75 | EGFR (0.43) | RAB9APRMT5WDR77SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011143106-A1 | BI - FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | CCR5 99/4885LMNA 1669/4885RAB9A 1281/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | CCR5 112/4885LMNA 2050/4885RAB9A 1164/4885 |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | CCR5 139/4885LMNA 3062/4885RAB9A 2210/4885 |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | CCR5 139/4885LMNA 3062/4885RAB9A 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.